لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Minturn, Robert J., Bracha, Peter, Klein, Margaret J., Chhablani, Jay, Harless, Ashley M., Maturi, Raj K.

الوصف: Additional file 3: Table S1. Average Change in CST over Time. Repeated Measures ANCOVA, Exploring the Baseline Covariates

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dee731c57f5798dae015b16844203f0

المؤلفون: Minturn, Robert J., Bracha, Peter, Klein, Margaret J., Chhablani, Jay, Harless, Ashley M., Maturi, Raj K.

مصطلحات موضوعية: sense organs, skin and connective tissue diseases, human activities

الوصف: Additional file 1: Figure S1. Adjusted Mean Change in CST by Treatment Group (95% C.I.). This figure demonstrates the adjusted mean change in CST in anti-VEGF and sirolimus groups

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d5eec5fe719a520b20d01d217581fe7

المؤلفون: Minturn, Robert J., Bracha, Peter, Klein, Margaret J., Chhablani, Jay, Harless, Ashley M., Maturi, Raj K.

مصطلحات موضوعية: sense organs, skin and connective tissue diseases

الوصف: Additional file 2: Figure S2. Adjusted Mean Change in VA by Treatment Group (95% Confidence Intervals). This figure demonstrates the change in visual acuity for each group over the course of the treatment. This was not found to be statistically significant.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90ba8842079cfeb2811a5a9179c4255f

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Maturi, Raj, Jaffe, Glenn J., Ehlers, Justis P., Kaiser, Peter K., Boyer, David S., Heier, Jeffrey S., Kornfield, Julia A., Kuppermann, Baruch D., Quiroz-Mercado, Hugo, Aubel, Janine, Karageozian, Lisa, Karageozian, Vicken H., Sarayba, Melvin

مصطلحات موضوعية: genetic structures, eye diseases

الوصف: Purpose : Risuteganib is a small synthetic peptide that regulates select integrin functions involved in the pathogenesis of dry age-related macular degeneration (AMD). This study evaluated the safety and efficay of risuteganib for the treatment of dry AMD. Methods : Randomized, double-masked, placebo-controlled Phase 2 study in eyes with intermediate dry AMD presenting with best-corrected visual acuity (BCVA) between 20/40-20/200 was conducted across multiple centers in the United States. Patients were randomized to receive either intravitreal 1.0mg risuteganib or sham injection at baseline. At week 16, patients in the risuteganib group received a second dose and the sham group crossed over and receive a single dose of 1.0mg risuteganib. The primary endpoint was the percentage of population with ≥ 8 letters BCVA gain from baseline to week 28 in 1.0mg risuteganib vs baseline to week 12 for sham. Results : Forty-five patients were enrolled in the study. At baseline, mean patient age was 78.8 and 75.9 years and mean baseline BCVA was 67.1 and 64.4 letters in the sham and risuteganib groups, respectively. The primary endpoint was met; 48% of patients in the risuteganib group at week 28 and 7% of patients in the sham group at week 12 gained > 8 letters from baseline (p=0.013). Of the risuteganib treated patients, 20% gained > 15 letters at week 28; no patients in the sham group at week 12 had this gain. On a post-hoc masked analysis by 2 independent reading centers, greater outer retinal and photoreceptor thickness and volume and smaller ellipsoid zone defect area in the central 1 mm zone at baseline were associated with increased BCVA response to risuteganib. Risuteganib demonstrated a good safety profile in this study. Conclusions : Risuteganib showed significant benefit over sham in patients with dry AMD with respect to proportion of patients gaining > 8 letters of BCVA from baseline. Furthermore, post hoc analysis provides preliminary insights into baseline anatomic features that may help to determine likelihood of BCVA response to risuteganib. These findings will be confirmed in an upcoming larger trial.

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od________38::32b26710ded4134e2c7a5ca38741b5df
https://resolver.caltech.edu/CaltechAUTHORS:20200921-142348069